Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Lead Candidate**: Nvudusitinib, a next-generation TYK2 inhibitor - **Focus**: Treatment of moderate to severe plaque psoriasis and potential applications in other immune-mediated diseases Key Points from the Call Clinical Results - **Phase 3 Results**: Positive outcomes for Nvudusitinib, exceeding Phase 2 results with statistically significant efficacy on primary and secondary endpoints [4][5] - **Efficacy Metrics**: - 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at week 16 [12] - Approximately 65% achieved PASI 90 and over 40% achieved PASI 100 at week 24 [12] - **Safety Profile**: Favorable safety and tolerability consistent with Phase 2 data, with most adverse events being mild to moderate [13] Market Opportunity - **Psoriasis Market**: Expected to reach $40 billion by 2030, with many patients currently underserved [6] - **Treatment Landscape**: Less than 20% of patients receive systemic treatment, and only 8% are treated with high-efficacy drugs [21] - **Patient Preferences**: 75% of patients prefer oral therapies over biologics, highlighting the demand for convenient treatment options [24] Future Developments - **NDA Filing**: Anticipated in the second half of 2026, pending data from the randomized withdrawal portion of the Phase 3 trial [37] - **Additional Trials**: Plans for a pivotal Phase 2b trial in systemic lupus erythematosus (SLE) with top-line data expected in Q3 2026 [6][28] - **Pipeline Expansion**: Development of A005, a CNS-penetrant TYK2 inhibitor, with a Phase 2 trial in multiple sclerosis planned for the first half of the year [27] Competitive Landscape - **Comparison with Competitors**: Nvudusitinib shows competitive efficacy compared to other oral therapies, including Icotrokinra and Apremilast [32][50] - **Mechanism of Action**: TYK2 inhibition may provide additional benefits beyond IL-23 and IL-17 pathways, particularly in itch reduction [51] Strategic Insights - **Market Positioning**: Alumis aims to position Nvudusitinib as a leading oral therapy for psoriasis, addressing significant unmet needs in the market [20][25] - **Partnership Considerations**: The company is evaluating strategic partnerships to maximize the asset's value, particularly in light of its broad potential across multiple indications [54] Additional Considerations - **Patient-Reported Outcomes**: Improvements in quality of life and itch were noted, which are critical factors for patient satisfaction [5][19] - **Regulatory Strategy**: Ongoing discussions with the FDA regarding the NDA filing and statistical analysis plans [38] Conclusion - **Outlook for 2026**: Alumis anticipates significant value inflection with the advancement of Nvudusitinib and its broader pipeline, aiming to address the substantial unmet needs in the treatment of psoriasis and other immune-mediated diseases [77]